论文信息 - LB0003 Tocilizumab (TCZ) monotherapy is superior to adalimumab (ADA) monotherapy in reducing disease activity in patients with rheumatoid arthritis (RA): 24-week data from the phase 4 adacta trial - 字舞流文

LB0003 Tocilizumab (TCZ) monotherapy is superior to adalimumab (ADA) monotherapy in reducing disease activity in patients with rheumatoid arthritis (RA): 24-week data from the phase 4 adacta trial

P. Emery | S. Agarwal | A. Kavanaugh | C. Gabay | R. V. van Vollenhoven | R. Alten | D. Musselman | M. Klearman | A. Dikranian | J. Green